Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion 2 – Immunotherapy of cancer

2580 - Analysis of Tumor Hyperprogression (HP) With Nivolumab (Nivo) in Randomized, Placebo (Pbo)-Controlled Trials


30 Sep 2019


Poster Discussion 2 – Immunotherapy of cancer



Tumour Site

Non-Small Cell Lung Cancer


Martin Reck


Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253


M. Reck1, Y. Feng2, H.R. Kim3, G. Plautz4, Y. Kang5, T.K. Owonikoko6, P. Nghiem7, J. Sheng8

Author affiliations

  • 1 Thoracic Oncology, LungenClinic, Airway Research Center North (ARCN), German Center of Lung Research (DZL), 22927 - Grosshansdorf/DE
  • 2 Clinical Pharmacology, Bristol-Myers Squibb, 08648 - Lawrenceville/US
  • 3 Division Of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, 03722 - Seoul/KR
  • 4 Global Pharmacovigilance And Epidemiology, Bristol-Myers Squibb, 08648 - Lawrenceville/US
  • 5 Department Of Oncology, University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 6 Department Of Hematology And Medical Oncology, Winship Cancer Institute of Emory University, 30322 - Atlanta/US
  • 7 Department Of Medicine And Dermatology, University of Washington & Fred Hutchinson Cancer Research Center, 98109 - Seattle/US
  • 8 Clinical Pharmacology & Pharmacometrics, Oncology, Bristol-Myers Squibb, 08648 - Lawrenceville/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2580


Tumor HP has been suggested to occur in some patients with solid tumors subsequent to PD-1/L1 inhibitor monotherapy; however, reports are based on nonrandomized, single-arm studies. Previous post-hoc analysis of HP with nivo was performed in the phase III ATTRACTION-2 trial, which randomized patients with gastric cancer who received ≥2 prior lines of therapy to nivo or pbo. Using the pbo arm as a surrogate for natural course of disease progression, nivo was not associated with HP at ≥ 20, ≥50, or ≥ 100% tumor growth rates. The current analysis expands this framework to assess HP in patients with extensive disease small cell lung cancer (ED SCLC) in the randomized, pbo-controlled CheckMate 451 trial.


CheckMate 451 was a phase III double-blind study that evaluated maintenance treatment in patients with ED SCLC without disease progression after platinum-based 1L chemotherapy. Patients were randomized to nivo 240 mg, nivo 1 mg/kg + ipilimumab 3 mg/kg, or pbo, within 9 weeks from the last dose of 1L chemotherapy (or ≤ 11 weeks for those receiving PCI or whole brain radiotherapy); HP analysis focused on the nivo (n = 280) and pbo (n = 275) arms. Tumor assessments occurred every 6 weeks for the first 36 weeks, then every 12 weeks until disease progression. HP was calculated as changes in size of the primary lesion (sum of longest diameters [SLD]), as assessed retrospectively among patients who had baseline and ≥1 on-treatment tumor measurement available (nivo, n = 177; pbo, n = 175).


Baseline characteristics were balanced between treatment arms in the analysis population. Median increase in tumor size from baseline to first on-treatment assessment in the maintenance period was 2% with nivo vs 17% with pbo. Compared to the pbo arm, fewer patients on nivo had SLD increases of ≥20% (27% vs 46%), ≥50% (10% vs 22%), and ≥100% (3% vs 6%) at the first on-treatment scan.


In this analysis, nivo was not associated with HP in the pbo-controlled CheckMate 451 trial. These data are consistent with the previous analysis of ATTRACTION-2, suggesting that reports of HP with immunotherapy may reflect some patients’ natural course of disease.

Clinical trial identification

CheckMate 451 trial: NCT02538666.

ONO-4538-12/ATTRACTION-2 trial: NCT02267343.

Editorial acknowledgement

Stephen Gutkin and Jay Rathi, MA, of Spark Medica Inc, funded by Bristol-Myers Squibb.

Legal entity responsible for the study

Bristol-Myers Squibb and ONO Pharmaceutical Co. Ltd.


Bristol-Myers Squibb and ONO Pharmaceutical Co. Ltd.


M. Reck: Honoraria (self): AbbVie; Honoraria (self): Amgen ; Honoraria (self): AstraZeneca ; Honoraria (self): Boehringer Ingelheim; Honoraria (self): BMS ; Honoraria (self): Celgene; Honoraria (self): Lilly ; Honoraria (self): Merck; Honoraria (self): MSD; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): Roche. Y. Feng: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. H.R. Kim: Honoraria (self), Advisory / Consultancy, Honoraria, consulting or advisory role: AstraZeneca; Honoraria (self), Advisory / Consultancy, Honoraria, consulting or advisory role: Roche; Honoraria (self), Advisory / Consultancy, Honoraria, consulting or advisory role: Boehringer Ingelheim. G. Plautz: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. Y. Kang: Advisory / Consultancy: Ono ; Advisory / Consultancy: BMS; Advisory / Consultancy: Daehwa; Advisory / Consultancy: LSKBiopharma; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: MacroGenics ; Advisory / Consultancy: Zymeworks; Advisory / Consultancy: Blueprint; Advisory / Consultancy: Merck Serono; Advisory / Consultancy: Novartis; Advisory / Consultancy: Astellas; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Novartis. T.K. Owonikoko: Research grant / Funding (institution): Novartis, Astellas Pharma, Celgene, Bayer, Stemcentrx, Regeneron, AstraZeneca/MedImmune, AbbVie, G1 Therapeutics, Bristol-Myers Squibb, Corvus Pharmaceuticals, United Therapeutics, Amgen, Loxo/Lilly, Fujifilm, Pfizer, Aeglea BioTherapeutics, Incyte, Merck; Advisory / Consultancy: Novartis, Celgene, Lilly, Sandoz, AbbVie, Eisai, G1 Therapeutics, Takeda, Seattle Genetics, Bristol-Myers Squibb, MedImmune, BerGenBio, Lilly, Amgen, AstraZeneca, PharmaMar, Boehringer Ingelheim, EMD Serono, Xcovery, Bayer, Heron Pharmaceutical, ARMO Bi; Shareholder / Stockholder / Stock options, Co-founder: Cambium Oncology. P. Nghiem: Honoraria (self), Honoraria for consulting: EMD Serono-Pfizer, Merck, Regeneron-Sanofi; Research grant / Funding (institution): EMD Serono, Bristol-Myers Squibb. J. Sheng: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.